MERRIMACK PHARMACEUTICALS INC financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2024.

Latest financial report
15 May 2024
Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge, MA
SEC filing record 1 source field available
Fiscal year end
31 December

Shareable Research Card

MERRIMACK PHARMACEUTICALS INC Financial Facts

MERRIMACK PHARMACEUTICALS INC has a source-backed company facts page for reviewing reported financial metrics, periods, and linked metric histories.

Start with the latest metric summary, then open metric histories or cross-company rankings to compare the same SEC-backed facts.

Context
Latest metrics period: Q1 2024
Latest reported value
Current Ratio 10.78x

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.

Open stable link Open latest 10-Q/10-K hub

Return Loop

Why revisit this company facts page

Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.

Latest source-backed update
Latest metrics period Q1 2024
Why come back
Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
  • Current latest metrics period: Q1 2024.
  • Most recent SEC facts end date on this page: 31 Mar 2024.
  • Save this filer to return when the next filing-backed metric period changes the picture.

Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.

Create account to save this filer Open latest 10-Q/10-K hub

Latest update

Latest update for MERRIMACK PHARMACEUTICALS INC

New fact period available

Latest financial period: Q1 2024. Reopen this facts page to verify the newest reported period against the prior baseline.

Update date

15 May 2024

Page type

Company facts

Latest period

Q1 2024

SEC-backed company facts were refreshed from filings filed on 15 May 2024.

Open recent updates hub Open latest 10-Q/10-K hub

Benchmark Context

How Current Ratio compares

Current Ratio is down about 75% versus the comparable prior period.

Compared with

Compared with MERRIMACK PHARMACEUTICALS INC's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.

Why this is notable

Current Ratio already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.

  • Latest comparable period on this page: Q1 2024.
  • Peer context will appear when enough companies report a comparable value for this metric.
  • Open the metric history first if you want to verify the exact period-to-period change.

Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.

Open latest 10-Q/10-K hub

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it

Key facts

  • MERRIMACK PHARMACEUTICALS INC financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q1 2024.
  • Headline metric: Current Ratio 10.78x.

Change

  • Current Ratio YoY change: -75%.
  • Most recent SEC facts end date: 31 Mar 2024.

Research use

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Evidence

Based on latest 10-Q/10-K

Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.

View source filing

Latest SEC snapshot (2024-03-31) highlights Current Ratio 10.78x and Debt-to-equity 0.09x.

Valuation Snapshot

SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.

No market comparison
DCF estimate is unavailable because required valuation inputs are missing. Missing: Free cash flow.

Data confidence notes

  • Free cash flow unavailable: operating cash flow or capex is missing
  • Ticker missing for issuer
  • Valuation unavailable: free cash flow is missing

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

55.6/100

Caution Confidence low

Financial Health

Current Ratio
10.78x
Debt to Equity
0.09x

Strengths

Debt-to-equity

Watchpoints

Current Ratio

Key metrics snapshot

Financial Health

Metric Latest value YoY change
Current Ratio 10.78x -75%
Debt-to-equity 0.09x +190%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 14,531,760 +1.9%
Common Stock, Shares, Outstanding 14,532,000 +1.9%
Common Stock, Value, Issued $1,345,000 +0.15%
Weighted Average Number of Shares Outstanding, Basic 14,452,000 +1.4%
Weighted Average Number of Shares Outstanding, Diluted 14,452,000 +1.4%

Supporting Metrics

These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.

Metric Latest value YoY change
Accounts Payable, Current $168,000 +89%
Accrued Liabilities, Current $161,000 +18%
Assets $244,322,000 +1144%
Assets, Current $244,319,000 +1145%
Cash and Cash Equivalents, at Carrying Value $234,160,000 +1107%
Cash, Cash Equivalents, and Short-term Investments $244,100,000 +1158%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $234,160,000 +1107%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $228,171,000
Common Stock, Par or Stated Value Per Share 0.01 0%
Common Stock, Shares Authorized 30,000,000 0%
Common Stock, Shares, Issued 14,532,000 +1.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $200,460,000
Earnings Per Share, Basic 14
Earnings Per Share, Diluted 14
General and Administrative Expense $2,259,000 +3.5%
Liabilities $22,672,000 +4797%
Liabilities and Equity $244,322,000 +1144%
Liabilities, Current $22,672,000 +4797%
Net Cash Provided by (Used in) Financing Activities $1,485,000 +730%
Net Cash Provided by (Used in) Investing Activities $228,000,000 +163929%
Net Cash Provided by (Used in) Operating Activities $1,314,000 -269%
Nonoperating Income (Expense) $925,000 +32%
Operating Income (Loss) $2,259,000 -11%
Other Assets, Noncurrent $3,000 -57%
Preferred Stock, Par or Stated Value Per Share 0.01 0%
Preferred Stock, Shares Authorized 10,000,000 0%
Preferred Stock, Shares Issued 0
Preferred Stock, Shares Outstanding 0
Retained Earnings (Accumulated Deficit) $347,447,000 +37%
Stockholders' Equity Attributable to Parent $221,650,000 +1056%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .